Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.76)
# 142
Out of 5,045 analysts
47
Total ratings
68.09%
Success rate
31.84%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $37.56 | +70.39% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $29.13 | +16.72% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $8.33 | +68.07% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.84 | +238.54% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $9.71 | +13.29% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $7.00 | +57.14% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $2.04 | +47.06% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.79 | +150.90% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $13.31 | +27.72% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $18.25 | +53.42% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $18.55 | +110.24% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.50 | +433.33% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $9.40 | +123.40% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $3.90 | +53.85% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $7.40 | +62.16% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.12 | +63.40% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $18.83 | +22.15% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.92 | +30.43% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $37.56
Upside: +70.39%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $29.13
Upside: +16.72%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $8.33
Upside: +68.07%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.84
Upside: +238.54%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $9.71
Upside: +13.29%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $7.00
Upside: +57.14%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $2.04
Upside: +47.06%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.79
Upside: +150.90%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $13.31
Upside: +27.72%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $18.25
Upside: +53.42%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.55
Upside: +110.24%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $1.50
Upside: +433.33%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $9.40
Upside: +123.40%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $3.90
Upside: +53.85%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $7.40
Upside: +62.16%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $6.12
Upside: +63.40%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $18.83
Upside: +22.15%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.92
Upside: +30.43%